Literature DB >> 12644702

Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Douglas D Richman1, Terri Wrin, Susan J Little, Christos J Petropoulos.   

Abstract

A recombinant virus assay was used to characterize in detail neutralizing antibody responses directed at circulating autologous HIV in plasma. Examining serial plasma specimens in a matrix format, most patients with primary HIV infection rapidly generated significant neutralizing antibody responses to early (0-39 months) autologous viruses, whereas responses to laboratory and heterologous primary strains were often lower and delayed. Plasma virus continually and rapidly evolved to escape neutralization, indicating that neutralizing antibody exerts a level of selective pressure that has been underappreciated based on earlier, less comprehensive characterizations. These data argue that neutralizing antibody responses account for the extensive variation in the envelope gene that is observed in the early months after primary HIV infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12644702      PMCID: PMC153062          DOI: 10.1073/pnas.0630530100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates.

Authors:  J A Kessler; P M McKenna; E A Emini; C P Chan; M D Patel; S K Gupta; G E Mark; C F Barbas; D R Burton; A J Conley
Journal:  AIDS Res Hum Retroviruses       Date:  1997-05-01       Impact factor: 2.205

2.  Decay characteristics of HIV-1-infected compartments during combination therapy.

Authors:  A S Perelson; P Essunger; Y Cao; M Vesanen; A Hurley; K Saksela; M Markowitz; D D Ho
Journal:  Nature       Date:  1997-05-08       Impact factor: 49.962

3.  Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients.

Authors:  D V Havlir; S Eastman; A Gamst; D D Richman
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1.

Authors:  J P Moore; Y Cao; D D Ho; R A Koup
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

5.  Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group.

Authors:  M P D'Souza; D Livnat; J A Bradac; S H Bridges
Journal:  J Infect Dis       Date:  1997-05       Impact factor: 5.226

6.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

Authors:  A Trkola; A B Pomales; H Yuan; B Korber; P J Maddon; G P Allaway; H Katinger; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus.

Authors:  T Wrin; L Crawford; L Sawyer; P Weber; H W Sheppard; C V Hanson
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-03

8.  HIV-specific cellular and humoral immune responses in primary HIV infection.

Authors:  E Connick; D G Marr; X Q Zhang; S J Clark; M S Saag; R T Schooley; T J Curiel
Journal:  AIDS Res Hum Retroviruses       Date:  1996-08-10       Impact factor: 2.205

9.  Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys.

Authors:  D P Burns; C Collignon; R C Desrosiers
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

10.  Viral dynamics in human immunodeficiency virus type 1 infection.

Authors:  X Wei; S K Ghosh; M E Taylor; V A Johnson; E A Emini; P Deutsch; J D Lifson; S Bonhoeffer; M A Nowak; B H Hahn
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

View more
  616 in total

1.  Autologous neutralizing antibody to human immunodeficiency virus-1 and replication-competent virus recovered from CD4+ T-cell reservoirs in pediatric HIV-1-infected patients on HAART.

Authors:  Natascha Ching; Karin A Nielsen-Saines; Jaime G Deville; Lian S Wei; Eileen Garratty; Yvonne J Bryson
Journal:  AIDS Res Hum Retroviruses       Date:  2010-05       Impact factor: 2.205

2.  Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV.

Authors:  Mark D Hicar; Xuemin Chen; Bryan Briney; Jason Hammonds; Jaang-Jiun Wang; Spyros Kalams; Paul W Spearman; James E Crowe
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

3.  Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1.

Authors:  Gülsen Ozkaya Sahin; Birgitta Holmgren; Zacarias da Silva; Jens Nielsen; Salma Nowroozalizadeh; Joakim Esbjörnsson; Fredrik Månsson; Sören Andersson; Hans Norrgren; Peter Aaby; Marianne Jansson; Eva Maria Fenyö
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

4.  Enhanced HIV-1 neutralization by antibody heteroligation.

Authors:  Hugo Mouquet; Malte Warncke; Johannes F Scheid; Michael S Seaman; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-04       Impact factor: 11.205

Review 5.  Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

6.  Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity.

Authors:  Zelda Euler; Tom L G M van den Kerkhof; Marit J van Gils; Judith A Burger; Diana Edo-Matas; Pham Phung; Terri Wrin; Hanneke Schuitemaker
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

Review 7.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

8.  Roles of fragment crystallizable-mediated effector functions in broadly neutralizing antibody activity against HIV.

Authors:  Ali Danesh; Yanqin Ren; R Brad Jones
Journal:  Curr Opin HIV AIDS       Date:  2020-09       Impact factor: 4.283

9.  Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaques.

Authors:  Yin Xu; Chris Weatherall; Michelle Bailey; Sheilajen Alcantara; Robert De Rose; Jerome Estaquier; Kim Wilson; Kazuo Suzuki; Jacques Corbeil; David A Cooper; Stephen J Kent; Anthony D Kelleher; John Zaunders
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

Review 10.  T Follicular Regulatory Cells and Antibody Responses in Transplantation.

Authors:  Elizabeth F Wallin
Journal:  Transplantation       Date:  2018-10       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.